HUTCHMED (China) Limited ADR Dossier - Source-backed chat

HUTCHMED (China) Limited ADR

HCMNASDAQ

SectorHealth Care

IndustryDrug Manufacturers - Specialty & Generic

Beta (adjusted)0.49

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $14.57Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $2.5B

Enterprise Value $2.6B

Moat Rating None

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

HUTCHMED is transitioning into a self-sustaining, profitable global biopharmaceutical leader. Backed by a robust cash position of $1.4 billion (bolstered by the strategic divestment of its 45% stake in SHPL), the company is well-positioned to fund its next-generation Antibody-Targeted Therapy Conjugate (ATTC) platform. Commercial execution remains strong, highlighted by the rapid global expansion of FRUZAQLA (partnered with Takeda) and a deep pipeline of late-stage assets with near-term regulatory catalysts in China and globally.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets14 analysts · as of 18 Aug 2026

Low · most bearish analyst$11.10

Mean target$20.99

High · most bullish analyst$40.40

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The bear case reflects potential regulatory delays for pipeline candidates (such as further manufacturing validation requirements for sovleplenib), intense competition in the MET inhibitor market, or slower-than-expected commercial ramp-up of newly launched products. Increased R&D spending on the ATTC platform without timely licensing deals could also pressure cash reserves.

Base CaseCentral scenario

The base case assumes steady commercial growth of FRUZAQLA in global markets and a recovery of ELUNATE sales in China. Sovleplenib receives NMPA approval for ITP, and the SAFFRON Phase III trial yields positive results in H2 2026, validating the global potential of savolitinib. The company maintains its path toward financial self-sufficiency while advancing early-stage ATTC assets.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong balance sheet with $1.4 billion in cash, providing a multi-year runway to accelerate R&D without dilutive financing.
Validated commercial execution with FRUZAQLA ex-China in-market sales growing 26% YoY to $366.2 million in 2025.
Deep late-stage pipeline with multiple near-term catalysts, including the SAFFRON Phase III readout in H2 2026 and regulatory filings for sovleplenib.
Established global partnerships with top-tier pharmaceutical companies, including Takeda, AstraZeneca, and Eli Lilly.

Key Investment Risks

Regulatory risks associated with clinical trial outcomes and potential delays in drug approvals by the NMPA, FDA, or EMA.
Fierce competition in the oncology space, particularly from other selective MET and VEGFR inhibitors.
Geopolitical and macroeconomic risks related to operating across China, the US, and Europe.

Thesis Invalidation Triggers

Failure of the SAFFRON Global Phase III trial to meet its primary endpoints.
Significant regulatory rejection or prolonged delay of sovleplenib's NDA in China.
A material slowdown in global FRUZAQLA sales or termination of key partnerships by Takeda or AstraZeneca.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.